InterPAD - DETAILS

Saxagliptin, Onglyza, 361442-04-8, BMS-477118, Saxagliptin [INN], BMS 477118, OPC-262, Saxagliptin anhydrous, 8I7IO46IVQ, CHEMBL385517, DTXSID7048580, CHEBI:71272, (1S,3S,5S)-2-((2S)-2-Amino-2-(3-hydroxyadamantan-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carbonitrile, (1S,3S,5S)-2-((2S)-Amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrile, (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, Saxagliptin?, (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, 1073057-20-1, UNII-8I7IO46IVQ, Saxagliptine, HSDB 8199, OPC 262, NCGC00242597-01, SAXAGLIPTIN [MI], Saxagliptin (USAN/INN), SCHEMBL17168, SAXAGLIPTIN [WHO-DD], MLS006011223, GTPL6316, DTXCID3028506, SCHEMBL20243458, BDBM11542, QGJUIPDUBHWZPV-SGTAVMJGSA-N, HMS3264P11, Pharmakon1600-01502500, 2-Azabicyclo[3.1.0]hexane-3-carbonitrile,2-[(2S)-amino(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1S,3S,5S)-, SBMS-477118, Tox21_112908, BDBM50225074, NSC760407, s1540, Saxagliptin (BMS-477118,Onglyza), AKOS015896547, AC-6008, CCG-213084, CCG-267647, CS-0650, DB06335, EX-7795, NCGC00242597-02, NCGC00242597-10, 2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1S,3S,5S)-, HY-10285, SMR004702984, AM20090693, CAS-361442-04-8, FT-0660429, D08996, EN300-761487, AB01562984_01, AB01562984_02, Q3121121, BRD-A81513827-001-03-6, Z2235802036, (S)-3-Hydroxyadamantylglycine-L-cis-4,5-methanoprolinenitrile TFA salt, (1S,6S)-2-(2-adamantan-1-yl-2-amino-acetyl)-2-aza-bicyclo[3.1.0]hexane-3-carbonitrile, (1S,3S,5S)-2-((2S)-AMINO(3-HYDROXYTRICYCLO(3.3.1.1(SUP 3,7))DEC-1-YL)ACETYL)-2-AZABICYCLO(3.1.0)HEXANE-3-CARBONITRILE, (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; 2,2,2-trifluoroacetic acid, (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-1-oxoethyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, (1S,3S,5S)-2-[(S)-2-amino-2-(3-hydroxy-adamantan-1-yl)-acetyl]-2-aza-bicyclo[3.1.0]hexane-3-carbonitrile, 2-AZABICYCLO(3.1.0)HEXANE-3-CARBONITRILE, 2-((2S)-AMINO(3-HYDROXYTRICYCLO(3.3.1.1(SUP 3,7))DEC-1-YL)ACETYL), (1S,3S,5S)-, 2-Azabicyclo(3.1.0)hexane-3-carbonitrile, 2-((2S)-amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl) , (1S,3S,5S)-

Name	Saxagliptin
PubChem CID	11243969
Molecular Weight	315.4g/mol
Synonyms	Saxagliptin, Onglyza, 361442-04-8, BMS-477118, Saxagliptin [INN], BMS 477118, OPC-262, Saxagliptin anhydrous, 8I7IO46IVQ, CHEMBL385517, DTXSID7048580, CHEBI:71272, (1S,3S,5S)-2-((2S)-2-Amino-2-(3-hydroxyadamantan-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carbonitrile, (1S,3S,5S)-2-((2S)-Amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)-2-azabicyclo(3.1.0)hexane-3-carbonitrile, (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, Saxagliptin?, (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, 1073057-20-1, UNII-8I7IO46IVQ, Saxagliptine, HSDB 8199, OPC 262, NCGC00242597-01, SAXAGLIPTIN [MI], Saxagliptin (USAN/INN), SCHEMBL17168, SAXAGLIPTIN [WHO-DD], MLS006011223, GTPL6316, DTXCID3028506, SCHEMBL20243458, BDBM11542, QGJUIPDUBHWZPV-SGTAVMJGSA-N, HMS3264P11, Pharmakon1600-01502500, 2-Azabicyclo[3.1.0]hexane-3-carbonitrile,2-[(2S)-amino(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1S,3S,5S)-, SBMS-477118, Tox21_112908, BDBM50225074, NSC760407, s1540, Saxagliptin (BMS-477118,Onglyza), AKOS015896547, AC-6008, CCG-213084, CCG-267647, CS-0650, DB06335, EX-7795, NCGC00242597-02, NCGC00242597-10, 2-Azabicyclo[3.1.0]hexane-3-carbonitrile, 2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-, (1S,3S,5S)-, HY-10285, SMR004702984, AM20090693, CAS-361442-04-8, FT-0660429, D08996, EN300-761487, AB01562984_01, AB01562984_02, Q3121121, BRD-A81513827-001-03-6, Z2235802036, (S)-3-Hydroxyadamantylglycine-L-cis-4,5-methanoprolinenitrile TFA salt, (1S,6S)-2-(2-adamantan-1-yl-2-amino-acetyl)-2-aza-bicyclo[3.1.0]hexane-3-carbonitrile, (1S,3S,5S)-2-((2S)-AMINO(3-HYDROXYTRICYCLO(3.3.1.1(SUP 3,7))DEC-1-YL)ACETYL)-2-AZABICYCLO(3.1.0)HEXANE-3-CARBONITRILE, (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile; 2,2,2-trifluoroacetic acid, (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-1-oxoethyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, (1S,3S,5S)-2-[(S)-2-amino-2-(3-hydroxy-adamantan-1-yl)-acetyl]-2-aza-bicyclo[3.1.0]hexane-3-carbonitrile, 2-AZABICYCLO(3.1.0)HEXANE-3-CARBONITRILE, 2-((2S)-AMINO(3-HYDROXYTRICYCLO(3.3.1.1(SUP 3,7))DEC-1-YL)ACETYL), (1S,3S,5S)-, 2-Azabicyclo(3.1.0)hexane-3-carbonitrile, 2-((2S)-amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl) , (1S,3S,5S)-
Drug Type	Small molecule
Formula	C₁₈H₂₅N₃O₂
SMILES	C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N
InChI	1S/C18H25N3O2/c19-8-13-2-12-3-14(12)21(13)16(22)15(20)17-4-10-1-11(5-17)7-18(23,6-10)9-17/h10-15,23H,1-7,9,20H2/t10?,11?,12-,13+,14+,15-,17?,18?/m1/s1
InChIKey	QGJUIPDUBHWZPV-SGTAVMJGSA-N
CAS Number	361442-04-8
ChEMBL ID	CHEMBL385517
ChEBI ID	CHEBI:71272
TTD ID	D0K9MY
Drug Bank ID	DB06335
KEGG ID	D08996
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Niacinamide, Saxagliptin
Partner Name	Niacinamide
Result	The efficacy of insulin and other antidiabetic agents may be diminished by certain drugs, including atypical antipsychotics, corticosteroids, diuretics, estrogens, gonadotropin-releasing hormone agonists, human growth hormone, phenothiazines, progestins, protease inhibitors, sympathomimetic amines, thyroid hormones, L-asparaginase, alpelisib, copanlisib, danazol, diazoxide, isoniazid, megestrol, omacetaxine, phenytoin, tagraxofusp, temsirolimus, as well as pharmacologic dosages of nicotinic acid and adrenocorticotropic agents. These drugs may interfere with blood glucose control because they can cause hyperglycemia, glucose intolerance, new-onset diabetes mellitus, and/or exacerbation of preexisting diabetes.